|19th January 2021||Vincent O'Neill||12,665||Open or private sale||$49.27||$624,004.55|
|19th January 2021||Vincent O'Neill||1,377||Open or private sale||$52.45||$72,223.65|
|19th January 2021||Vincent O'Neill||2,700||Open or private sale||$50.38||$136,026.00|
|19th January 2021||Vincent O'Neill||1,500||Open or private sale||$51.45||$77,175.00|
|19th January 2021||Vincent O'Neill||25,000||Exercise of derivative||$0.41||$10,250.00|
|19th January 2021||Vincent O'Neill||6,758||Open or private sale||$48.43||$327,289.94|
|28th December 2020||Vincent O'Neill||3,951||Open or private sale||$52.68||$208,138.68|
|28th December 2020||Vincent O'Neill||13,969||Open or private sale||$50.77||$709,206.13|
|28th December 2020||Vincent O'Neill||1,353||Open or private sale||$53.54||$72,439.62|
|28th December 2020||Vincent O'Neill||25,000||Exercise of derivative||$0.41||$10,250.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company focuses on drug development. The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.